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Abstract 
 
Purpose 
 
People with severe asthma experience significant respiratory symptoms and suffer 
adverse effects of oral corticosteroids (OCS), including disturbed mood and physical 
symptoms. The impact of OCS on health-related quality of life (HRQoL) has not been 
quantified. Asthma HRQoL scales are valid as outcome measures for patients requiring 
OCS only if they assess the deficits imposed by OCS. This study compared the burden 
of disease and treatment in patients with severe asthma with items in 8 asthma specific 
HRQoL scales. 
Methods 
 
23 patients with severe asthma recruited from a severe asthma clinic were interviewed 
about the impact of their respiratory symptoms and the burden of their treatment. 
Patients’ reports were compared with the items of eight established asthma-specific 
HRQoL scales. 
  
Results 
 
In addition to the burden caused by symptoms, ten domains of OCS impact on HRQoL 
were identified: depression, irritability, sleep, hunger, weight, skin, gastric, pain, 
disease anxiety, medication anxiety. Impact varied and for some was substantial. 
Although all HRQoL scales include some OCS-relevant items, all eight scales fail to 
adequately assess the several types of burden experienced by some patients while on 
OCS. 
Conclusion 
 
Existing asthma HRQoL scales provide an over-positive estimation of HRQOL in 
patients with frequent exposure to OCS and underestimate the benefit of interventions 
that reduce OCS exposure. Apart from global HRQoL scale usage, bias can be avoided 
either by designing burden-specific questionnaires to be used alongside existing scales 
or by designing scales where the burdens of symptoms and medication are compared 
using equivalent response scales. 
Keywords: Severe asthma; difficult asthma; quality of life; QALY; validity; assessment 
  
Bias in the assessment of quality of life in severe asthma due to the burden of oral 
corticosteroids 
Health related quality of life (HRQoL) is one of several outcome measures used to 
inform treatment guidelines for asthma, and is unique amongst outcome measures in 
that it informs whether treatment is worthwhile from the perspective of the patient[1]. 
Asthma-specific HRQOL scales have content validity to the extent that items in the 
scale assess the range of deficits experienced by patients with asthma. Content validity 
confers sensitivity to changes following an intervention: treatment benefit will be 
underestimated if content validity and sensitivity to change are poor. Asthma-specific 
HRQoL scales tend to be more sensitive to change than generic scales because they 
exclude items which are unlikely to change following treatment, and because generic 
scales do not include specific items relating to potential asthma improvement[2, 3]. 
The majority of patients with asthma have mild-to-moderate disease and the potential 
to be well-controlled with existing therapies (inhaled corticosteroids and 
bronchodilators). However, severe asthma is a much more heterogenous condition and 
is increasingly recognised as qualitatively different from mild-to-moderate asthma. 
These patients are more challenging to manage and are more likely to require treatment 
with oral corticosteroids (OCS). If the HRQoL deficits of asthma vary only in degree 
between mild, moderate and severe patients, then a scale which has shown to be valid 
and sensitive to change in mild and moderate patient should also be valid for patients 
with severe asthma – assuming that items are chosen to avoid floor or ceiling effects. 
However, if severe asthma patients have uniquely different types of HRQoL deficits, 
  
then a scale that omitted those deficits would not be valid for severe patients, even 
though it might be valid for mild or moderate patients. 
All published asthma HRQoL scales contain items relating to the burden of asthma (i.e., 
activity restriction and emotional impact of asthma), and some include one or more 
items relating to the impact of treatment. The impact of OCS is known to be far greater 
than the impact of other asthma treatments[4, 5], and therefore severe patients, i.e., 
those who require maintenance or frequent bursts of high dose OCS, are likely to have 
a greater treatment burden than other patients. OCS are known to have direct effects on 
mood (e.g., depression, suicidal ideation, anxiety) as well as physical effects (e.g., 
weight gain) that also can have psychological implications[6-8]. It is unclear whether 
the burden of treatment is adequately measured by existing scales. If existing scales fail 
to assess the impact of OCS on HRQoL, then this will lead to overestimation of the 
effectiveness of OCS and underestimation of the benefit of steroid-sparing treatments. 
The aim of this study was to characterise the burden of asthma and its treatment in this 
patient group, to determine the extent to which items in existing asthma-specific scales 
provide a valid assessment of the patient experience. 
Methods 
 
Patients were recruited from a specialist severe asthma clinic at Derriford hospital, 
Plymouth, UK if they were on Step 4 or 5 of British Thoracic Society treatment 
guidelines and invited to take part in a study where they would be asked about their 
experience of asthma and its treatment. Patients were purposefully sampled to represent 
  
different age groups and social backgrounds. Patients were asked about their 
experience of asthma, their experience of medication and their treatment at the clinic, 
but with specific reference to the impact of OCS. The number of patients interviewed 
was determined by content saturation. Audio from interviews was recorded and 
transcribed, anonymised, and analysed by thematic analysis. Ethical approval and 
written informed consent were obtained. 
Eight asthma-specific HRQoL scales were examined, of which six commonly feature in 
systematic reviews[9]. These are the Juniper Asthma Quality of Life Questionnaire 
(AQLQJuniper)[10] ; the mini AQLQ[11]; the Living with Asthma Questionnaire 
(LWAQ)[12]; the St George’s Respiratory Questionnaire (SGRQ)[13]; the Marks 
Asthma Quality of Life Questionnaire (AQLQMarks)[14]; the Asthma Questionnaire 
which is in two forms: the 30 item AQ30 and a 20 item subset, the AQ20[15]. We 
supplemented these six with two additional scales: The Asthma Bother Profile 
(ABP)[16] was developed for clinical use, where side effect concerns are relevant to 
adherence, and has additionally the been used as an outcome tool[17,18]. The Asthma 
Specific Quality of Life Scale (ASQLS)[19], is a recently-published scale, the 
development of which involved extensive qualitative research on asthma HRQoL 
domains. 
  
Results 
 
 
Patient characteristics 
 
53 patients were identified as suitable for interview; 40 patients were contacted, 28 
agreed to take part, 23 were interviewed, and 12 declined to take part for several 
reasons, including work commitments, child care, and health. Patients are labelled P1 
to P23 in order of interview. Characteristics of the 23 patients interviewed are shown in 
Table 1. 
Results of the thematic analysis 
 
The content of interviews revealed two overarching themes: the impact of asthma, and 
the impact of medication. Impact of asthma could be divided into three domains: 
activities, emotional impact, and hospitalisation. OCS created the greatest impact on 
patients; patients reported only minor effects of other medications for their asthma or 
for other conditions. The effects of OCS could be divided into ten domains: depression, 
irritability, sleep, hunger, weight, skin, gastric, pain, disease anxiety, medication 
anxiety. 
Impact of asthma 
 
Many patients experienced activity restriction, activity avoidance and emotional impact 
of asthma but, while some were very severe, they were not qualitatively different from 
patients with mild or moderate asthma. A third domain of hospitalisation was reported 
by 19 patients: unpredictable repeated hospitalisation disrupted patients’ lives, 
  
particularly those with parental responsibilities, and made planning difficult. In 
addition, patients’ disliked being in hospital and the associated treatment required, and 
felt less cared-for than when treated by staff at the severe asthma clinic who had a 
better understanding of their disease. 
Impact of medication 
 
Patients reported side effects only in association with OCS. Other asthma medication 
was perceived to have no or trivial effects. 
Depression 
 
 
P1, P10, and P15 experienced severe depression and attributed it to the effect of 
steroids (P1: “I know I was never depressed before I started on steroids”; P10 “I can’t 
tell you how much I hate being on them because of the depression”). P15, P16, P19 
reported the onset or increase in depression when reducing their OCS dose, and P10 
reported that depression extended beyond the period in which they took OCS (P10: “it 
seems to last a good couple of weeks when I’ve come off them, even if I tail them off 
gently”). P5 and P8 reported depression but attributed it to their increased weight (P5: 
“I suppose it’s where a lot of my depression comes from: because you get fat, your 
clothes don’t fit”). P6 and P23 experienced depression but were unsure whether or not 
it was caused by OCS. 
Irritability and inability to rest or relax 
  
Irritability caused by OCS was reported by P1, P2, P5, P6, P10, P16, P19, P20, P21, 
P22. (P10: “[I’m] Like a Rottweiler on heat! I am oh, it’s worse than any menopausal 
or premenopausal or anything like that. My poor husband ….I’ve cried, I’ve said, I 
wish I was dead, you’d be better off without me”. P16: “I’ve been more irritable since 
I’ve been on steroids.” ) 
 
 
 
Sleep disturbance 
 
 
Sleep disturbance due to the arousing effect of OCS was reported by P6, P7, P9, P12, 
P15. P19, P21 and P22. (P6: “I never sleep properly when I am on steroids”). P6 and 
P19 reported being easily woken (P6: “any sound wakes me up”). P9 and P15 reported 
not sleeping at all during the first night of a course of OCS  (P15: I don’t sleep.  I’m 
just hyper”). P17 reported that she used to experience sleep disturbance but had become 
used to it, and P20 reported sleep disturbance caused by severe hunger, that she 
attributed to OCS. 
Hunger and disturbed eating patterns 
 
 
Increased levels of hunger due to OCS were reported by 16 of the 23 patients (P1, P5, 
P6, P7, P8, P9, P10, P14, P15, P16, P18, P19, P20, P21, and P22). P22 reported 
hunger on 40mg but not 5mg prednisolone. P1 and P8 reported that the hunger was 
associated with a feeling of sickness (P8: “I get to feeling sick all day… it’s a really, 
really weird combination”), and both of these patients reported vomiting due to 
  
overeating (P1: the amount of times I’ve been physical sick because of it, it’s a 
complete nightmare”). P16 reported eating things she did not like when on OCS. P5 
and P9 reported hunger for about one week after terminating OCS. 
Impact of weight gain and Cushingoid appearance 
 
 
Fourteen patients mentioned weight gain as a problem. P3, P14, P17 and P22 reported 
that they had not experienced weight gain and only slight weight gain was reported by 
P19. Patients reported that their increased weight was embarrassing (P5: “My weight 
thing is the big thing. It sounds so stupid, but I’ve had years of people going on about 
how fat I am”). P2 showed the interviewer a picture of herself before being put on 
steroids (P2: “Until then, 12 months ago I looked like this”). 
P6, P15 and P23 reported that the increased weight made the effects of asthma worse 
(P6: It doesn’t help the breathing does it, when you’ve got more to carry….. Am I 
wheezing because I’m wheezing, or am I wheezing because I am carrying all this 
excess weight?”. P15: “Obviously, the more weight you’re carrying the more breathing 
problems you’re having. So it’s a Catch-22”). 
 
 
Impact of skin thinning 
 
 
P10, P16, P18, P20 and P23 reported bruising easily, and P16 and P18 reported that 
they modified their behaviour to avoid bruising (P16: “I’ve got to be careful where I 
walk. You know like little handles on doors, corners on things … I do just bump into 
  
things because I sometimes don’t think properly where I’m going. But a door handle 
will give me a bruise.”) 
Gastric problems 
 
 
P4, P5, P7, P8, P9 and P12 reported stomach bloating, P7 and P9 reported wind, and P8 
and P9 reported constipation. P4, P8, P12, and P15 reported stomach pain. 
Pain 
 
 
P1, P2 and P21 reported pain attributed to fractures. P11, P15 and P19 reported pain 
when their OCS was reduced (P11: “If I suddenly went off prednisolone completely 
now, as I have done in the past, you find that all sorts of aches and pains come back”. 
P15: “I cannot manage without the maintenance dose. I can’t let [husband] touch me 
because my skin feels as if it’s all bruising”. P19: “If I take them off quickly, I get pain 
– really awful pains in my joints and muscles….. Basically, if someone just touches me, 
it hurts – I mean everywhere”). 
Anxiety about future disease course 
 
 
P5, P6, P10 and P16 expressed concerns about the future (P5: “I mean I just worry that 
 
I wouldn’t be around with my kids when they’re little”. P6: “Yes I do worry, you know, 
asthma kills, it does. You do worry about it sometimes”). 
Medication anxiety 
  
P4, P5, P6, P8, P9, and P13 expressed concerns about the long-term effects of OCS (P4: 
“I feel that it’s poisoning my system”. P9: “I’m getting immune to them I think”). 
Additional comments 
 
Some patients indicated that OCS had a greater impact on their lives than asthma 
symptoms. One patient (P2) indicated she would trade 15 years of life if she did not 
need to take OCS with asthma symptoms remaining constant, and two (P9, P16) would 
trade 10 years. 
Comparison with existing asthma-specific HRQoL scales 
 
All 8 HRQoL scales contain items assessing the impact of asthma symptoms in the 
domains of activities and emotions. No scale contains any items specifically referring 
to hospitalisation. Table 2 shows the number of items in each of the eight asthma- 
specific HRQoL scales that potentially could measure the impact of OCS in each of the 
10 OCS domains of impact identified in this study. All scales could potentially 
measure the impact of sleep disturbance, but measurement of other domains is either 
absent for all scales or limited to a few. Three scales contain non-specific items 
relating to the general negative effect of medication on HRQoL. 
Discussion 
 
OCS use in asthma is known to be associated with psychological and physical side 
effects[4, 5]. While patients may or may not be correct when attributing the causes of 
symptoms, these attributions are likely to affect satisfaction with treatment and 
  
adherence. The type of impact of OCS varied between patients, but emotional impacts 
were comparatively common. Ten patients reported irritability, five reported depression 
directly attributed to the use of steroids, and a further two reported depression as a 
consequence of weight gain. Eight patients reported sleep disturbance due to the 
arousing effects of OCS, with a further one patient reporting sleep disturbance due to 
the effects of hunger. Of the 14 patients reporting hunger, two reported vomiting due to 
overeating, and one reported indiscriminate eating. OCS had an impact on patients’ 
lives also when the dose was reduced or discontinued, with three patients reporting pain 
sensitisation under these circumstances, and three reporting depression. Three patients 
reported that the increased weight caused by OCS exacerbated their asthma symptoms. 
These results are broadly consistent with previous research showing that the burden of 
treatment in severe asthma is primarily due to the impact of OCS, and the major form 
of impact is in terms of psychological disturbance[4]. Additionally, this research 
highlights the dynamical interaction between OCS and depression, the disturbed eating 
patterns rather than just hunger, the effect of central pain sensitisation (in 3/23 patients) 
when reducing OCS dose, and gastric symptoms attributed by patients to OCS. 
With the possible exception of hospitalisation, we found little evidence that the burden 
of asthma symptoms is qualitatively different in the severe asthma population 
compared to other populations and existing scales are valid for the severe population in 
that respect. 
With regard to the burden of asthma treatment, the results are more complex. All of the 
existing scales had items relating to sleep disturbance. Sleep disturbance can arise for 
  
at least two reasons – due to breathlessness/cough and due to the arousing effect of oral 
steroids (or less commonly, due to increased hunger). The sleep items of four of the 
scales (including the AQLQJuniper and the mini-AQLQ) are worded in such a way that 
either cause would be reported. Depression was not assessed in either the AQLQJuniper 
or mini-AQLQ, but was assessed in some other scales (see Table 2). Depression was a 
major impact in some patients and is a recognised side effect of OCS. Depression in 
asthma can result from three causes – depression due to limitations caused by asthma 
symptoms; a direct effect of OCS on depression; and the indirect, depressive effects of 
altered body image and self-concept. For those scales where depression is assessed 
(i.e., Living with Asthma Questionnaire, the AQLQMarks, and the Asthma Bother 
Profile), any cause of depression would elicit a patient response. 
Although we identified 10 domains of HRQoL deficit caused by OCS, it is possible 
that these deficits are measured by items in existing scales that refer more generally to 
‘medication’. Neither the mini-AQLQ nor the AQLQMarks have items relating to 
medication. The SGRQ has two items and the Asthma-Specific Quality of Life Scale 
has one item relating to the effect of medication on life. Other scales had items relating 
to medication embarrassment or bother, but not to their impacts. The AQLQJuniper has 
one item relating to concern about use of medication, but not related to impact. Only 
the LWAQ has an item that could relate to weight gain, and none have items relating to 
hunger or disturbed patterns of eating, the impact of skin thinning, gastric problems, 
and pain. Irritability was found to be a common and troubling symptom, but only the 
  
LWAQ and the AQ30 have items that measure this aspect of the patient’s experience, 
and then only by referring to restlessness and an inability to relax. 
The impact of OCS is entirely or almost entirely neglected in the scales most frequently 
used in clinical trials (ACLQJuniper and mini-AQLQ). Other outcome measures, 
including spirometry and asthma control questionnaires, fail to measure the impact of 
treatment as perceived by the patient, and therefore fail to assess that uniquely 
important feature of HRQoL measurement: whether the treatment is worthwhile from 
the perspective of the patient[1]. 
HRQoL scales are used for two purposes: as an outcome measure and which can be 
used to make resourcing decisions and as a guide to clinical practice. Both purposes 
are better served if the impact of asthma symptoms and asthma medication are assessed 
together. In the short term it seems advisable to use a global HRQoL scale alongside 
existing scales. However, global scales tend be less sensitive to change than disease 
specific scales as the latter (should) optimise items in relation to quality of life burden. 
For the future, two strategies are possible. One is to develop treatment burden scales 
that can be used alongside an existing asthma HRQoL scale, and which has the 
potential to be used for other diseases where OCS is used in severe cases. The other is 
to develop a new scale where the burdens of symptoms and medication are 
simultaneously measured along equivalent scales. For example, sleep disturbance can 
be caused by either asthma symptoms or the effect of OCS, and measurement on 
separate equivalent scales allows the clinician to compare how patients perceive the 
  
advantages and disadvantages of medication. Figure 1 shows a possible design of such 
a questionnaire, a design that could help clinicians manage non-adherence. 
Conclusions: 
 
The use of existing asthma-specific scales in populations of severe asthma patients 
creates two kinds of bias. First, in cross-sectional studies, the total burden of asthma on 
HRQoL in these patients will be underestimated in comparison with less severe patients. 
Second the benefit of OCS on HRQoL will be overestimated and the benefit of steroid 
sparing agents underestimated. These biases have implications for treatment 
recommendations in terms of resources allocated to severe asthma patients and choices 
made about the use of modern steroid sparing agents, these being substantially more 
expensive than OCS. The bias in current measurement can be remedied in part by the 
use of global HRQoL scales (global HRQoL questionnaires typically fail to measure, 
for example, the effects of abnormal hunger), or preferably by developing treatment 
burden questionnaires or by developing a new type of HRQoL scale for severe asthma 
where the burden of symptoms and treatment can be compared using equivalent 
response scales. 
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Table 1 Characteristics of patients of the 23 patients interviewed. 
 
 
 
N (gender) 23 (19 female, 4 male) 
 
Mean age – years (age at 
diagnosis) 
Mean FEV1 – Litres 
(range) 
Mean FEV1 %Predicted 
(range) 
N prescribed maintenance 
OCS 
Mean daily dose for those 
on maintenance OCS 
(mg/d) (range) 
N adherence with oral 
steroids measured by 
serum 
prednisolone/cortisol (%) 
50.95 years (28-70) 
(20 years) 
1.74 L (0.56 – 2.78) 
 
 
62% (30-90) 
 
 
15/23 
 
 
15.3 mg/d (5-60mg) 
 
 
 
12 tested of whom 11 
(92%) were compliant, 1 
partially compliant. 
Mean BMI – Kg/m2(range) 30.1 (21.1 – 48.4) 
 
Mean MiniAQLQ* score 
(range) 
4.54 (1.7 – 5.7) 
 
Mean ACT** score (range) 14.47 (5 - 23) 
 
*mini asthma quality of life questionnaire 
 
**asthma control test 
  
Table 2. Number of questions in 8 asthma specific quality of life scales corresponding 
to each of the 10 domains of OCS impact. 
 
Domains 
 
 
 
 
 
 
 
No. of items in questionnaire 32 15 68 76 20 15 30 112 
Depression 0 0 1 0 1 2 0 1 
Irritability 0 0 1 0 0 0 1 0 
Sleep 1 1 1 1 1 1 1 4 
Hunger 0 0 0 0 0 0 0 0 
Weight 0 0 1 0 0 0 0 0 
Skin 0 0 0 0 0 0 0 0 
Gastric 0 0 0 0 0 0 0 0 
Pain 0 0 0 0 0 0 0 0 
Disease anxiety 0 0 1 0 2 1 0 2 
Medication anxiety 1 0 1 0 0 0 1 1 
Non-specific items about medication 0 0 0 3 0 2 0 1 
 
 
AQLQJuniper : Asthma Quality of Life Questionnaire[10]; MiniAGLQ: Mini Asthma 
Quality of Life Questionnaire[11]; LWAQ: Living With Asthma Questionnaire[12]; 
SGRQ: St Georges Respiratory Questionnaire[13]; AQLQMarks : Asthma Quality of Life 
Questionnaire[14]; AQ30: Asthma Questionnaire-30[15]; ABP: Asthma Bother 
Profile[16]; ASQLS: Asthma specific quality of life scale[19]. 
*The ABP has an additional 7 management items. **The AQ20 has 20 items 
comprising a subset of the AQ30. 
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Figure 1: Design of questionnaire to measure asthma symptoms and 
medication symptoms using equivalent scales. 
 
 
 
Patients respond on scale: 
 
 1 2 3 4 
Not at all 
5 6 7 
Makes life 
a misery 
List of items relating to domains 
identified for both asthma 
symptoms, effects of medication, 
or both 
Because of my 
asthma 
symptoms… 
 
Because of my 
asthma 
medicines…. 
 
I am restricted in my social life 
 
   
  
   
I am restricted in my personal life    
 
   
I get depressed    
 
   
I get irritable    
 
   
Etc.    
 
   
Etc.    
 
   
Etc.    
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